David Westenberg
Stock Analyst at Piper Sandler
(4.34)
# 364
Out of 4,962 analysts
172
Total ratings
54.55%
Success rate
15.92%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACB Pacific Biosciences of California | Maintains: Neutral | $1.25 → $1.5 | $1.32 | +13.64% | 9 | Aug 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $210 → $215 | $155.19 | +38.54% | 15 | Aug 11, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $510 → $700 | $641.35 | +9.14% | 11 | Aug 11, 2025 | |
| ELAN Elanco Animal Health | Maintains: Neutral | $12 → $18 | $17.79 | +1.18% | 10 | Aug 11, 2025 | |
| NTRA Natera | Maintains: Overweight | $210 → $220 | $162.47 | +35.41% | 16 | Aug 11, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $70 → $60 | $45.66 | +31.41% | 11 | Aug 11, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $13 → $15 | $12.67 | +18.39% | 14 | Aug 6, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $11 | $6.45 | +70.54% | 10 | Aug 4, 2025 | |
| WGS GeneDx Holdings | Maintains: Overweight | $110 → $120 | $121.87 | -1.53% | 2 | Aug 4, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $23 → $21 | $21.48 | -2.23% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $70 | $75.90 | -7.77% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $185 | $99.66 | +85.63% | 16 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $260 → $280 | $276.11 | +1.41% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $61.88 | -3.04% | 9 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $200 | $178.66 | +11.94% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.4 → $5 | $5.60 | -10.71% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8.5 → $8 | $4.11 | +94.65% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $14.07 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $27.65 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $45.83 | - | 1 | Nov 21, 2017 |
Pacific Biosciences of California
Aug 11, 2025
Maintains: Neutral
Price Target: $1.25 → $1.5
Current: $1.32
Upside: +13.64%
Zoetis
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $215
Current: $155.19
Upside: +38.54%
IDEXX Laboratories
Aug 11, 2025
Maintains: Neutral
Price Target: $510 → $700
Current: $641.35
Upside: +9.14%
Elanco Animal Health
Aug 11, 2025
Maintains: Neutral
Price Target: $12 → $18
Current: $17.79
Upside: +1.18%
Natera
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $220
Current: $162.47
Upside: +35.41%
Exact Sciences
Aug 11, 2025
Maintains: Overweight
Price Target: $70 → $60
Current: $45.66
Upside: +31.41%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Overweight
Price Target: $13 → $15
Current: $12.67
Upside: +18.39%
NeoGenomics
Aug 4, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $6.45
Upside: +70.54%
GeneDx Holdings
Aug 4, 2025
Maintains: Overweight
Price Target: $110 → $120
Current: $121.87
Upside: -1.53%
Fulgent Genetics
Aug 4, 2025
Maintains: Neutral
Price Target: $23 → $21
Current: $21.48
Upside: -2.23%
May 15, 2025
Maintains: Neutral
Price Target: $55 → $70
Current: $75.90
Upside: -7.77%
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $99.66
Upside: +85.63%
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $276.11
Upside: +1.41%
May 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $61.88
Upside: -3.04%
Apr 28, 2025
Maintains: Neutral
Price Target: $180 → $200
Current: $178.66
Upside: +11.94%
Apr 22, 2025
Maintains: Neutral
Price Target: $6.4 → $5
Current: $5.60
Upside: -10.71%
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $4.11
Upside: +94.65%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $14.07
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $27.65
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $45.83
Upside: -